Sonoma Pharmaceuticals (SNOA) Accumulated Expenses (2011 - 2026)

Sonoma Pharmaceuticals' Accumulated Expenses history runs 14 years deep, the most recent figure standing at $1.7 million for Q1 2026.

• On a quarterly basis, Accumulated Expenses fell 1.04% year-over-year to $1.7 million in Q1 2026; TTM through Mar 2026 was $1.7 million, a 1.04% decrease from a year earlier, with the FY2026 full-year figure at $1.7 million, down 1.04% from the prior year.
• Accumulated Expenses slipped to $1.7 million in Q1 2026 per SNOA's latest filing, from $1.7 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $1.7 million in Q1 2025 and bottomed at $1.1 million in Q1 2022.
• The 5-year median for Accumulated Expenses is $1.5 million (2023), against an average of $1.5 million.
• Across the five-year window, Accumulated Expenses jumped 38.15% in 2023 and fell 3.01% in 2024, its largest moves.
• Year by year, Accumulated Expenses stood at $1.1 million in 2022, then soared by 38.15% to $1.5 million in 2023, then decreased by 3.01% to $1.4 million in 2024, then rose by 22.41% to $1.7 million in 2025, then decreased by 1.04% to $1.7 million in 2026.
• Per Business Quant, the three latest SNOA Accumulated Expenses figures stand at $1.7 million (Q1 2026), $1.7 million (Q1 2025), and $1.4 million (Q1 2024).